HIV Infections Clinical Trial
Official title:
Assessment of Attentional Functioning in Children With HIV-1 Infection
Children with symptomatic HIV-1 (Human Immunodeficiency Virus) infection are at increased
risk for developing severely disabling neurological and neuropsychological deficits. HIV-1
related CNS (Central Nervous System) disease is a clinical syndrome, manifested by varying
and sometimes discordant degrees of cognitive, motor and behavioral impairment. A continuum
of clinical presentations attributed to the effects of HIV-1 infection on the CNS, ranging
from apparently normal development, decreases in the rate of new learning to the loss of
acquired skills have been observed. Two domains of psychological functioning appear most
susceptible to the effects of HIV infection on the central nervous system in children:
expressive behavior and attentional processes (Brouwers, et al, 1994).
Attention deficits have been documented as a relative weakness on the "freedom from
distractibility" subclass of IQ tests (Brouwers et al, 1989) and on behavior assessment
(Moss et al, 1994). Attention, however, has many subcomponents such as focused attention,
divided attention, vigilance, etc. Direct assessment of attentional functioning using
reaction time has not yet been conducted and questions whether attentional components are
differentially affected by the virus have not been addressed.
The proposed study would assess different components of attentional functioning in children
with HIV-1 disease. A quantitative and systematic method is developed that could complement
the existing standardized instruments used for measuring attention and neurocognitive
function in this population. Simple alerted visual reaction time will be measured with
varying preparatory intervals, a two-choice reaction time in a go/no-go paradigm will be
administered, and a continuous performance, divided reaction time test and an object
decision task will be given. Performance on these measures will also be related to measures
of brain structure and stage of HIV-1 disease.
Children with symptomatic HIV-1 (Human Immunodeficiency Virus) infection are at increased
risk for developing severely disabling neurological and neuropsychological deficits. HIV-1
related CNS (Central Nervous System) disease is a clinical syndrome, manifested by varying
and sometimes discordant degrees of cognitive, motor and behavioral impairment. A continuum
of clinical presentations attributed to the effects of HIV-1 infection on the CNS, ranging
from apparently normal development, decreases in the rate of new learning to the loss of
acquired skills have been observed. Two domains of psychological functioning appear most
susceptible to the effects of HIV infection on the central nervous system in children:
expressive behavior and attentional processes (Brouwers, et al, 1994).
Attention deficits have been documented as a relative weakness on the "freedom from
distractibility" subclass of IQ tests (Brouwers et al, 1989) and on behavior assessment
(Moss et al, 1994). Attention, however, has many subcomponents such as focused attention,
divided attention, vigilance, etc. Direct assessment of attentional functioning using
reaction time has not yet been conducted and questions whether attentional components are
differentially affected by the virus have not been addressed.
The proposed study would assess different components of attentional functioning in children
with HIV-1 disease. A quantitative and systematic method is developed that could complement
the existing standardized instruments used for measuring attention and neurocognitive
function in this population. Simple alerted visual reaction time will be measured with
varying preparatory intervals, a two-choice reaction time in a go/no-go paradigm will be
administered, and a continuous performance, divided reaction time test and an object
decision task will be given. Performance on these measures will also be related to measures
of brain structure and stage of HIV-1 disease.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |